ArticleJournal of hepatocellular carcinoma2026
Clinical Efficacy Exploration of Temperature-Sensitive Embolic Agent TACE Combined with HAIC and Targeted/Immunotherapy for Unresectable Primary Liver Cancer.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of TEM-TACE combined with HAIC and targeted/immunotherapy for the treatment of unresectable primary liver cancer, and to clarify the clinical application potential of this multimodal therapeutic regimen. Methods: This study was a small-sample retrospective case series. The clinical data of 4 patients with unresectable primary liver cancer who underwent TEM-TACE combined with HAIC and targeted/immunotherapy in our hospital from April 2025 to July 2025 were retrospectively analyzed. Tumor response was evaluated according to the mRECIST criteria, and the occurrence of adverse reactions was assessed on the basis of the Clavien-Dindo classification system. All patients included in this study provided written informed consent for the publication of their clinical details. Results: Among the 4 patients, 2 were diagnosed with HCC, and the other 2 were diagnosed with ICC. All 4 patients achieved a PR after treatment with TEM-TACE combined with HAIC and targeted/immunotherapy, with a mean tumor reduction of 42.3%. The ORR and DCR both reached 100%. Among these patients, 2 successfully achieved treatment conversion and underwent radical surgical resection, while the remaining 2 refused surgery for personal reasons. During the perioperative period, only Clavien-Dindo grade I-II complications (mainly abdominal pain and nausea) occurred in the 4 patients, which improved after symptomatic treatment, and no severe adverse reactions were observed. Conclusion: The multimodal therapeutic regimen of TEM-TACE combined with HAIC and targeted/immunotherapy is safe and effective for unresectable primary liver cancer. In particular, compared with conventional embolic agents, temperature-sensitive embolic agents enable precise peripheral embolization and sustained drug release, thereby significantly reducing tumor volume and improving the rate of conversion to surgical resection. Moreover, this regimen provides a novel approach for the conversion therapy of unresectable ICC. It is suitable for patients with primary liver cancer who have a tumor diameter >10 cm, liver function of Child-Pugh class A/B, and no severe comorbidities. However, further studies with larger sample sizes are still required to verify its long-term efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.